<DOC>
	<DOCNO>NCT00578214</DOCNO>
	<brief_summary>Midazolam approve sedative medication use medical procedure . This study do document safety efficacy midazolam improve anxiety , heart rate , blood pressure patient prior undergoing Mohs micrographic surgery treatment skin cancer ( basal cell carcinoma squamous cell carcinoma ) . Midazolam may make patient relaxed sleepy , low blood pressure . These effect last 2 hour . This study two part . In first part , eligible patient randomize either receive one standard dose midazolam syrup placebo syrup surgery , neither patient study team know patient receive study drug . In second part , patient eligible participate randomize study refuse participate randomize study enrol prospective arm know receive midazolam syrup . In prospective arm , dos base patient 's weight , patient give additional dos midazolam syrup necessary control anxiety . The primary hypothesis study single dose oral midazolam syrup patient prior undergoing outpatient Mohs micrographic surgery skin cancer would result low anxiety score 60 minute compare placebo . In addition , second hypothesis study patient give oral midazolam would rate adverse event worse 25 % high placebo group .</brief_summary>
	<brief_title>Safety Efficacy Oral Midazolam Perioperative Anxiety Relief Patients Undergoing Mohs Micrographic Surgery</brief_title>
	<detailed_description>The main objective study establish safety efficacy midazolam patient skin cancer undergo outpatient Mohs micrographic surgery . Patients randomize double-blind placebo-controlled study single-dose midazolam syrup efficacy produce safe anxiolysis short duration . A parallel prospective arm study involve administration midazolam unblinded fashion . Based available study orally administer midazolam , expectation observe adverse event minor major adverse event rate midazolam would similar placebo . Data collect vital sign , anxiety , adverse event , overall satisfaction anxiolytic agent .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 2 site biopsyconfirmed squamous cell basal cell carcinoma limited head neck region Inclusion Criteria Prospective Arm : Patients wish receive oral midazolam nonblinded fashion exclude base size individual tumor , total number tumor , prior history oral midazolam No upper weight limitation Prior history allergy midazolam syrup component History hypersensitivity benzodiazepine Congestive heart failure ( AHA Class III IV ) Renal failure require hemodialysis Endstage liver failure Chronic alcoholism alcohol intoxication within 24 hour surgery Untreated uncontrolled open angle glaucoma Uncontrolled hypertension History psychoses affective disorder Neuromuscular disorder myasthenia gravis Chronic obstructive pulmonary disease Patients medication interfere renal excretion microsomal metabolism unless last dose take great equal 5 halflives prior surgery Patients weigh less 100 lb ( 45 kg ) Pregnant woman ; woman childbearing potential require take inoffice urine pregnancy test . Breastfeeding mother must stop breastfeed 7 day take midazolam take part study Additional Exclusion Criteria Randomized Arms : Patients single cancer &gt; 5 cm great dimension 2 cancer Patients previously premedicated oral midazolam prior Mohs micrographic surgery episode Patients weigh 220 lb ( 100 kg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>mohs micrographic surgery</keyword>
	<keyword>skin cancer</keyword>
	<keyword>anxiety</keyword>
	<keyword>basal cell carcinoma</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>midazolam</keyword>
	<keyword>verse</keyword>
</DOC>